Zhejiang Hisun Pharmaceutical
HISUN is one of the local leading pharmaceutical companies in China.
Launch date
Employees
Market cap
€1.1b
Enterprise valuation
€1.5b (Public information from Sep 2024)
Share price
CNY7.13 600267.SS
China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 11.4b | 12.1b | 12.0b | 10.4b | 9.3b | 9.8b | 10.0b |
| % growth | 3 % | 7 % | (1 %) | (14 %) | (10 %) | 5 % | 2 % |
| EBITDA | 2.2b | 2.1b | 2.1b | 1.5b | 1.8b | 1.7b | 1.7b |
| % EBITDA margin | 20 % | 17 % | 18 % | 15 % | 19 % | 18 % | 17 % |
| Profit | 417m | 487m | 489m | (93.2m) | 426m | 731m | 459m |
| % profit margin | 4 % | 4 % | 4 % | (1 %) | 5 % | 7 % | 5 % |
| EV / revenue | - | - | 1.1x | 1.5x | 0.9x | 0.9x | 0.9x |
| EV / EBITDA | - | - | 6.0x | 10.1x | 4.9x | 5.1x | 5.3x |
| R&D budget | 401m | 373m | 429m | 392m | - | - | - |
| R&D % of revenue | 4 % | 3 % | 4 % | 4 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Zhejiang Hisun Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
